Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Cancer Prev Res (Phila). 2019 Jul 15;12(10):721–730. doi: 10.1158/1940-6207.CAPR-19-0006

Figure 3: Inflammation results.

Figure 3:

All biopsies received an inflammation score (0–3) at baseline and after 6 months of pioglitazone or placebo. Biopsies were analyzed in the following groups: baseline (BL) non-normal; matched pairs; reference sites; and all sites.